Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 30, 2025 08:00 ET | Source: Valitor, Inc.

Valitor Highlights Three-fold Increase with VLTR-559 in Sustained Potency and Durability over Aflibercept in Preclinical Ocular Wet AMD Models

-Data showcased in session titled “Spotlight on Drug Delivery” at the Ophthalmology Innovation Source (OIS) Retina 8th Annual Innovation Summit -VLTR-559, a long-acting anti-VEGF therapy, could...
May 07, 2025 08:00 ET | Source: Valitor, Inc.

Valitor Presents Multiple Preclinical Datasets on the Potential of its Innovative Anti-VEGF Therapy Dosed Twice Yearly for Wet AMD at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

-VLTR-559, a long-acting anti-VEGF therapy, could reduce dosing frequency for the treatment of wet AMD to twice-yearly, as compared to every eight to twelve weeks for standard-of-care anti-VEGFs...
April 30, 2025 08:00 ET | Source: Valitor, Inc.

Valitor to Present on its Drug Candidate with Twice-Yearly Dosing for Wet AMD at the American Academy of Ophthalmology’s Eyecelerator Conference and the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

BERKELEY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Valitor, a biotechnology company engineering a new generation of ophthalmic medicines, today announced its president and chief scientific...
August 12, 2024 16:05 ET | Source: Valitor, Inc.

Valitor to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

BERKELEY, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Valitor, a biotechnology company engineering better medicines to conquer drug limitations, today announced that president and chief scientific...
July 19, 2023 16:00 ET | Source: Valitor, Inc.

Valitor Expands Leadership Team with Appointment of Omkar Joshi, Ph.D. as Vice President of CMC

BERKELEY, Calif., July 19, 2023 (GLOBE NEWSWIRE) -- Valitor, a biotechnology company engineering better medicines to conquer drug limitations, today announced the appointment of Omkar Joshi,...
April 24, 2023 18:00 ET | Source: Valitor, Inc.

Valitor Presents Preclinical Data on its Long-acting Anti-VEGF Biologic in Development for Durable Treatment of Wet AMD at the Association for Research in Vision and Ophthalmology Annual Meeting

BERKELEY, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Valitor, a biotechnology company engineering better medicines to conquer drug limitations, today announced new data from VLTR-557, its...
April 10, 2023 08:00 ET | Source: Valitor, Inc.

Valitor to Present on the Potential for its Multivalent Polymer Technology to Expand the Therapeutic Index of Oncology Agents at the 2023 American Association for Cancer Research Annual Meeting

BERKELEY, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- Valitor, a biotechnology company engineering better medicines to conquer drug limitations, today announced that data reviewing the therapeutic...
March 23, 2023 08:00 ET | Source: Valitor, Inc.

Valitor to Present at the Association for Research in Vision and Ophthalmology Annual Meeting

BERKELEY, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Valitor, a biotechnology company engineering better medicines to conquer drug limitations, today announced that two abstracts have been accepted...
December 01, 2022 16:00 ET | Source: Valitor, Inc.

Valitor Announces Presentation on Novel Anti-VEGF Antibody Conjugate and Multivalent Polymer Technology Platform at Upcoming Ophthalmology Innovation Source (OIS) Summit

BERKELEY, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Valitor, a biotechnology company engineering better medicines to conquer drug limitations, today announced that its president and chief scientific...
October 05, 2022 08:00 ET | Source: Valitor, Inc.

Valitor Announces the Closing of its Series B Financing and Names Steven Lo as Chief Executive Officer

BERKELEY, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Valitor, a biotechnology company engineering better medicines to conquer drug limitations, today announced that it has closed a Series B...